SCHEMBL863928

SCHEMBL863928

c1ccc2c(c1)CCN(Cc1ccc3c(c1)CC1(CCCN4CCCCC4C1)O3)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 5/20 0.38
WDR77 Q9BQA1 5/20 0.38
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
HPGD P15428 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
POLB P06746 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
NOS1 P29475 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863703 0.97 ALDH1A1 (0.39) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL7856753 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL863841 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL10191846 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL7856756 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL7856749 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL10191847 0.96 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL7856335 0.94 DRD2 (0.42) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL863482 0.89 DRD2 (0.41) PRMT5WDR77ALDH1A1NPSR1KDM4E
SCHEMBL10192278 0.86 MEN1 (0.43) ALDH1A1OPRM1TSHRHRH3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
WO-2010144571-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 PRMT5 2193/4885WDR77 791/4885ALDH1A1 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.